Bio
Eddie has a keen interest in integrating scientific advancements into modern medicine. He is currently the co-lead for Health Services Research at the Duke-NUS Centre of Regulatory Excellence (CoRE), where his team manages a project with Singapore’s Ministry of Health to address emerging healthcare topics.
Prior to joining CoRE, he had spent 6 years as the Scientific Officer in the National Cell Therapy Pilot Program housed under the Blood Services Group of the Health Sciences Authority of Singapore (HSA). In his role with HSA, Dr Eddie Tan is responsible for engaging with medical and scientific leaders to address Chemistry Manufacturing and Controls (CMC) matters to transform pre-clinical research into GMP-compliant manufacturing and early-phase clinical trials. From 2021 to 2024, he also held an appointment as a Cell Therapy Specialist covering Translational Services and Regulatory Management and was involved in the planning and establishment of the Advanced Cell Therapy Research Institute of Singapore (ACTRIS), as an effort to develop a new national GMP Facility for Cell and Gene Therapy Manufacturing.
He graduated with a BSc (Hons in Biological Sciences) and a PhD (Biological Sciences) from Nanyang Technological University in Singapore. He is a member of the inaugural batch of professionals awarded the Certified Advanced Biotherapies Professional (CABP) designation by AABB in 2022. He is also a registered member of The Organization of Professionals in Regulatory Affairs (MTOPRA).
Education
Doctor of Philosophy
Nanyang Technological University, Singapore
Bachelor (Science - Biological Sciences) Honours Class 1
Nanyang Technological University, Singapore